Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.
Identifieur interne : 000D86 ( Main/Corpus ); précédent : 000D85; suivant : 000D87Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.
Auteurs : Yan Chen ; Taipeng Shen ; Lijun Zhong ; Zhixi Liu ; Xinwei Dong ; Tingwenli Huang ; Qiuju Wang ; Hongtao XiaoSource :
- Frontiers in pharmacology [ 1663-9812 ] ; 2020.
Abstract
In December 2019, a severe outbreak of a novel coronavirus (COVID-19) occurred in the whole world, posing a great threat to people's health. With the outbreak and development of the epidemic, how to improve the cure rate, find effective drugs against this virus, has been the most urgent problem. Chloroquine (CQ) was verified effective against COVID-19 in vitro. As CQ's analogue, hydroxychloroquine (HCQ) was also reminded as a potential candidate for treating COVID-19. This review summarizes the latest clinical trials of CQ and HCQ against COVID-19 and its therapeutic regimen in China aiming to share their current usage to the whole world and provide insight into its appropriate future use in the treatment of COVID-19. Through searching the CNKI and Wangfang databases in Chinese language and PubMed, EMBASE, and Ovid databases in English language to identify published reports with the keywords including "coronavirus/COVID, chloroquine, hyroxychloroquine" in alone or combined, we found out the potential preclinical or clinical evidence for using CQ and HCQ against COVID-19. Consequently, we also searched the website of Chinese Clinical Trial Registry (http://www.chictr.org.cn/) till the day on 27th, June, 2020. This review found that there are 23 programs aimed to treat the different phases under COVID-19 pipeline in clinic with CQ and HCQ, totally. The inclusion criteria, exclusion criteria and therapeutic regimen were all shared to consult. Among them, seven have been canceled due to lack of patients or other objective factors. There are two trials have completed, which the potential relationship between usage and adverse reactions was discussed emphatically. Through literature research, we suggested that paid close attention to retinal toxicity and ophthalmologic adverse symptom of CQ and HCQ. And the outcome of HCQ in clinic shows better than CQ especially in protective effect with low dosage.
DOI: 10.3389/fphar.2020.01167
PubMed: 32848774
PubMed Central: PMC7412992
Links to Exploration step
pubmed:32848774Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.</title><author><name sortKey="Chen, Yan" sort="Chen, Yan" uniqKey="Chen Y" first="Yan" last="Chen">Yan Chen</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Shen, Taipeng" sort="Shen, Taipeng" uniqKey="Shen T" first="Taipeng" last="Shen">Taipeng Shen</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhong, Lijun" sort="Zhong, Lijun" uniqKey="Zhong L" first="Lijun" last="Zhong">Lijun Zhong</name><affiliation><nlm:affiliation>Department of Information, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Zhixi" sort="Liu, Zhixi" uniqKey="Liu Z" first="Zhixi" last="Liu">Zhixi Liu</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Dong, Xinwei" sort="Dong, Xinwei" uniqKey="Dong X" first="Xinwei" last="Dong">Xinwei Dong</name><affiliation><nlm:affiliation>Department of Information, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Huang, Tingwenli" sort="Huang, Tingwenli" uniqKey="Huang T" first="Tingwenli" last="Huang">Tingwenli Huang</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Qiuju" sort="Wang, Qiuju" uniqKey="Wang Q" first="Qiuju" last="Wang">Qiuju Wang</name><affiliation><nlm:affiliation>Department of Clinical Laboratory, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xiao, Hongtao" sort="Xiao, Hongtao" uniqKey="Xiao H" first="Hongtao" last="Xiao">Hongtao Xiao</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32848774</idno><idno type="pmid">32848774</idno><idno type="doi">10.3389/fphar.2020.01167</idno><idno type="pmc">PMC7412992</idno><idno type="wicri:Area/Main/Corpus">000D86</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D86</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.</title><author><name sortKey="Chen, Yan" sort="Chen, Yan" uniqKey="Chen Y" first="Yan" last="Chen">Yan Chen</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Shen, Taipeng" sort="Shen, Taipeng" uniqKey="Shen T" first="Taipeng" last="Shen">Taipeng Shen</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhong, Lijun" sort="Zhong, Lijun" uniqKey="Zhong L" first="Lijun" last="Zhong">Lijun Zhong</name><affiliation><nlm:affiliation>Department of Information, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Zhixi" sort="Liu, Zhixi" uniqKey="Liu Z" first="Zhixi" last="Liu">Zhixi Liu</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Dong, Xinwei" sort="Dong, Xinwei" uniqKey="Dong X" first="Xinwei" last="Dong">Xinwei Dong</name><affiliation><nlm:affiliation>Department of Information, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Huang, Tingwenli" sort="Huang, Tingwenli" uniqKey="Huang T" first="Tingwenli" last="Huang">Tingwenli Huang</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Qiuju" sort="Wang, Qiuju" uniqKey="Wang Q" first="Qiuju" last="Wang">Qiuju Wang</name><affiliation><nlm:affiliation>Department of Clinical Laboratory, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xiao, Hongtao" sort="Xiao, Hongtao" uniqKey="Xiao H" first="Hongtao" last="Xiao">Hongtao Xiao</name><affiliation><nlm:affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Frontiers in pharmacology</title><idno type="ISSN">1663-9812</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In December 2019, a severe outbreak of a novel coronavirus (COVID-19) occurred in the whole world, posing a great threat to people's health. With the outbreak and development of the epidemic, how to improve the cure rate, find effective drugs against this virus, has been the most urgent problem. Chloroquine (CQ) was verified effective against COVID-19 <i>in vitro</i>. As CQ's analogue, hydroxychloroquine (HCQ) was also reminded as a potential candidate for treating COVID-19. This review summarizes the latest clinical trials of CQ and HCQ against COVID-19 and its therapeutic regimen in China aiming to share their current usage to the whole world and provide insight into its appropriate future use in the treatment of COVID-19. Through searching the CNKI and Wangfang databases in Chinese language and PubMed, EMBASE, and Ovid databases in English language to identify published reports with the keywords including "coronavirus/COVID, chloroquine, hyroxychloroquine" in alone or combined, we found out the potential preclinical or clinical evidence for using CQ and HCQ against COVID-19. Consequently, we also searched the website of Chinese Clinical Trial Registry (http://www.chictr.org.cn/) till the day on 27<sup>th</sup>, June, 2020. This review found that there are 23 programs aimed to treat the different phases under COVID-19 pipeline in clinic with CQ and HCQ, totally. The inclusion criteria, exclusion criteria and therapeutic regimen were all shared to consult. Among them, seven have been canceled due to lack of patients or other objective factors. There are two trials have completed, which the potential relationship between usage and adverse reactions was discussed emphatically. Through literature research, we suggested that paid close attention to retinal toxicity and ophthalmologic adverse symptom of CQ and HCQ. And the outcome of HCQ in clinic shows better than CQ especially in protective effect with low dosage.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32848774</PMID><DateRevised><Year>2021</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.</ArticleTitle><Pagination><MedlinePgn>1167</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2020.01167</ELocationID><Abstract><AbstractText>In December 2019, a severe outbreak of a novel coronavirus (COVID-19) occurred in the whole world, posing a great threat to people's health. With the outbreak and development of the epidemic, how to improve the cure rate, find effective drugs against this virus, has been the most urgent problem. Chloroquine (CQ) was verified effective against COVID-19 <i>in vitro</i>. As CQ's analogue, hydroxychloroquine (HCQ) was also reminded as a potential candidate for treating COVID-19. This review summarizes the latest clinical trials of CQ and HCQ against COVID-19 and its therapeutic regimen in China aiming to share their current usage to the whole world and provide insight into its appropriate future use in the treatment of COVID-19. Through searching the CNKI and Wangfang databases in Chinese language and PubMed, EMBASE, and Ovid databases in English language to identify published reports with the keywords including "coronavirus/COVID, chloroquine, hyroxychloroquine" in alone or combined, we found out the potential preclinical or clinical evidence for using CQ and HCQ against COVID-19. Consequently, we also searched the website of Chinese Clinical Trial Registry (http://www.chictr.org.cn/) till the day on 27<sup>th</sup>, June, 2020. This review found that there are 23 programs aimed to treat the different phases under COVID-19 pipeline in clinic with CQ and HCQ, totally. The inclusion criteria, exclusion criteria and therapeutic regimen were all shared to consult. Among them, seven have been canceled due to lack of patients or other objective factors. There are two trials have completed, which the potential relationship between usage and adverse reactions was discussed emphatically. Through literature research, we suggested that paid close attention to retinal toxicity and ophthalmologic adverse symptom of CQ and HCQ. And the outcome of HCQ in clinic shows better than CQ especially in protective effect with low dosage.</AbstractText><CopyrightInformation>Copyright © 2020 Chen, Shen, Zhong, Liu, Dong, Huang, Wang and Xiao.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>TaiPeng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>LiJun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Information, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>ZhiXi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>XinWei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Information, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>TingWenLi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>QiuJu</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>HongTao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">chloroquine</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">potential risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32848774</ArticleId><ArticleId IdType="doi">10.3389/fphar.2020.01167</ArticleId><ArticleId IdType="pmc">PMC7412992</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curr Drug Targets. 2020;21(16):1703-1721</Citation><ArticleIdList><ArticleId IdType="pubmed">32552642</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Ophthalmol. 2011 Jan;129(1):30-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21220626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmology. 2011 Feb;118(2):415-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21292109</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2010 May;82(5):817-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20336760</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):677-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21550310</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Ophthalmol. 1992 Aug;27(5):237-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1393809</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochimie. 2020 Dec;179:237-246</Citation><ArticleIdList><ArticleId IdType="pubmed">32485205</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin J Am Soc Nephrol. 2018 May 7;13(5):702-709</Citation><ArticleIdList><ArticleId IdType="pubmed">29661770</ArticleId></ArticleIdList></Reference><Reference><Citation>Mil Med. 2006 Feb;171(2):131-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16578982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cureus. 2020 May 28;12(5):e8342</Citation><ArticleIdList><ArticleId IdType="pubmed">32494546</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Biomed Anal. 1988;6(5):521-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16867399</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation><ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2018 Oct;41(10):919-931</Citation><ArticleIdList><ArticleId IdType="pubmed">29858838</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1998 Jan;72(1):783-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9420287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation><ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>ScientificWorldJournal. 2013;2013:282734</Citation><ArticleIdList><ArticleId IdType="pubmed">23431254</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1983 Jul 18;75(1A):40-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6869410</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2007 Sep-Nov;1(5-6):189-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19453426</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2017 Nov;44(11):1674-1679</Citation><ArticleIdList><ArticleId IdType="pubmed">28864645</ArticleId></ArticleIdList></Reference><Reference><Citation>Malar J. 2011 May 24;10:144</Citation><ArticleIdList><ArticleId IdType="pubmed">21609473</ArticleId></ArticleIdList></Reference><Reference><Citation>J Interferon Cytokine Res. 2015 Mar;35(3):143-56</Citation><ArticleIdList><ArticleId IdType="pubmed">25321315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation><ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2018 May;72(5):e13095</Citation><ArticleIdList><ArticleId IdType="pubmed">29691971</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 1996 Oct;31(4):257-74</Citation><ArticleIdList><ArticleId IdType="pubmed">8896943</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 Sep 12;345(6202):1369-72</Citation><ArticleIdList><ArticleId IdType="pubmed">25214632</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Res Opin. 2015 Nov;31(11):2105-17</Citation><ArticleIdList><ArticleId IdType="pubmed">26371518</ArticleId></ArticleIdList></Reference><Reference><Citation>Trans R Soc Trop Med Hyg. 1990;84 Suppl 2:1-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2219249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2015 Dec;96(12):3484-3492</Citation><ArticleIdList><ArticleId IdType="pubmed">26459826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Dec;76(24):12866-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12438612</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Ophthalmol. 2014 Oct;132(10):1199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">24970348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2002 Jun 15;359(9323):2072-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12086760</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Trop Med. 2014 Dec;7(12):925-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25479619</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Allergy Asthma Rep. 2017 Feb;17(2):13</Citation><ArticleIdList><ArticleId IdType="pubmed">28233156</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation><ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ind Med Gaz. 1918 Jul;53(7):241-249</Citation><ArticleIdList><ArticleId IdType="pubmed">29006736</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Trop Med Hyg. 2020 Jun;102(6):1184-1188</Citation><ArticleIdList><ArticleId IdType="pubmed">32323646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Transl Med. 2020 May;8(10):637</Citation><ArticleIdList><ArticleId IdType="pubmed">32566574</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Omega. 2018 Dec 31;3(12):18132-18141</Citation><ArticleIdList><ArticleId IdType="pubmed">30613818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2018 Apr;27(5):847-852</Citation><ArticleIdList><ArticleId IdType="pubmed">28862574</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(4):e60579</Citation><ArticleIdList><ArticleId IdType="pubmed">23577127</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101735</Citation><ArticleIdList><ArticleId IdType="pubmed">32387694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Sep 23;368(9541):1096-105</Citation><ArticleIdList><ArticleId IdType="pubmed">16997664</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Haematol. 2020 Nov;105(5):655-658</Citation><ArticleIdList><ArticleId IdType="pubmed">32593209</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Ophthalmol. 2013 Sep;131(9):1187-97</Citation><ArticleIdList><ArticleId IdType="pubmed">23887202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2019 May;28(6):722-730</Citation><ArticleIdList><ArticleId IdType="pubmed">30971164</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2005 Aug;54(8):2404-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16046308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Chemother Pharmacol. 2017 Feb;79(2):287-294</Citation><ArticleIdList><ArticleId IdType="pubmed">27889812</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2020 May;26(5):1049-1052</Citation><ArticleIdList><ArticleId IdType="pubmed">32053479</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):223-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15076236</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmology. 2016 Jun;123(6):1386-94</Citation><ArticleIdList><ArticleId IdType="pubmed">26992838</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Apr;176:104742</Citation><ArticleIdList><ArticleId IdType="pubmed">32057769</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1988 Jan 7;318(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3336379</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Biomed Anal. 2005 Jun 1;38(1):21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15907614</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol. 1983 Mar-Apr;5(2):173-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6188885</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 20;43(0):E019</Citation><ArticleIdList><ArticleId IdType="pubmed">32075365</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2007 May 03;4:39</Citation><ArticleIdList><ArticleId IdType="pubmed">17477867</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2016 Nov 29;8(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">27916837</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 1997 Sep-Oct;19(5):913-23</Citation><ArticleIdList><ArticleId IdType="pubmed">9385480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2006 May 4;49(9):2845-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16640347</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 1996 Nov-Dec;18(6):1080-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9001825</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32848774
|texte= Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32848774" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |